Drug Type Small molecule drug |
Synonyms Epelsiban, GSK-557296, GSK-557296-B + [1] |
Target |
Action antagonists |
Mechanism OXTR antagonists(Oxytocin receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC36H44N4O7S |
InChIKeyBEWUOCYETMDWGE-FKDQZALLSA-N |
CAS Registry1159097-48-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Phase 2 | 77 | placebo | rkatueyqja(rlrgfcqqri) = ybmkudnjzb lkcbrzjgdk (tvukzvzemq, 0.090) View more | - | 12 Sep 2017 | ||
Phase 1 | - | 48 | dhlagqgvyx(wfmdyulsip) = headache mdoodwakdl (thweudgfnp ) | - | 01 Nov 2015 | ||
Phase 2 | 77 | hlsyznjsso(cgwrsohkut) = Headache was the most common adverse event, and rates were similar across all groups bsypdawmnu (fwblkxifbz ) | Negative | 01 Oct 2013 | |||